[Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D000077270:Exenatide; D005934:Glucagon / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007231:Infant, Newborn; D007333:Insulin Resistance; D008116:Lizards; D010446:Peptide Fragments / Q000008:administration & dosage / Q000378:metabolism*; D010455:Peptides / Q000627:therapeutic use*; D011498:Protein Precursors / Q000008:administration & dosage / Q000378:metabolism*; D013997:Time Factors; D014688:Venoms / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide; D005947:Glucose